Karyopharm Therapeutics Inc. (NASDAQ:KPTI - Get Free Report)'s share price passed below its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $0.92 and traded as low as $0.85. Karyopharm Therapeutics shares last traded at $0.85, with a volume of 316,258 shares.
Analyst Upgrades and Downgrades
KPTI has been the subject of several recent analyst reports. HC Wainwright reaffirmed a "buy" rating and issued a $7.00 price target on shares of Karyopharm Therapeutics in a research report on Wednesday, August 7th. Royal Bank of Canada reiterated an "outperform" rating and set a $3.00 target price on shares of Karyopharm Therapeutics in a research note on Wednesday, August 7th. StockNews.com raised shares of Karyopharm Therapeutics from a "hold" rating to a "buy" rating in a report on Thursday, August 8th. Finally, Robert W. Baird dropped their target price on Karyopharm Therapeutics from $8.00 to $5.00 and set an "outperform" rating on the stock in a research report on Wednesday, August 7th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $4.80.
Check Out Our Latest Stock Analysis on KPTI
Karyopharm Therapeutics Price Performance
The stock's 50-day simple moving average is $0.80 and its two-hundred day simple moving average is $0.92. The firm has a market capitalization of $105.64 million, a P/E ratio of -0.67 and a beta of 0.20.
Karyopharm Therapeutics (NASDAQ:KPTI - Get Free Report) last issued its quarterly earnings data on Tuesday, August 6th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.29) by $0.09. The firm had revenue of $42.79 million for the quarter, compared to analysts' expectations of $36.07 million. On average, analysts forecast that Karyopharm Therapeutics Inc. will post -0.93 earnings per share for the current fiscal year.
Institutional Trading of Karyopharm Therapeutics
Hedge funds have recently made changes to their positions in the business. Ikarian Capital LLC lifted its stake in shares of Karyopharm Therapeutics by 2.3% in the 1st quarter. Ikarian Capital LLC now owns 409,355 shares of the company's stock valued at $618,000 after purchasing an additional 9,355 shares during the last quarter. Point72 DIFC Ltd bought a new stake in Karyopharm Therapeutics in the second quarter worth $31,000. Exchange Traded Concepts LLC increased its position in Karyopharm Therapeutics by 34.9% during the third quarter. Exchange Traded Concepts LLC now owns 218,791 shares of the company's stock valued at $182,000 after acquiring an additional 56,613 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Karyopharm Therapeutics in the 2nd quarter worth about $143,000. Finally, Acadian Asset Management LLC bought a new position in Karyopharm Therapeutics during the 2nd quarter valued at about $167,000. 66.44% of the stock is currently owned by hedge funds and other institutional investors.
Karyopharm Therapeutics Company Profile
(
Get Free Report)
Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).
Featured Articles
Before you consider Karyopharm Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Karyopharm Therapeutics wasn't on the list.
While Karyopharm Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
